Navigation Links
CEL-SCI's Cel-1000 Shown to Significantly Enhance Immune Response,Against Hepatitis B Antigen in Animals

VIENNA, Va., May 01, 2007 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION announces that CEL-1000 alone increased the immune response against hepatitis B antigen, and that the combination of CEL-1000 with MAS-1, a proprietary water-in-oil adjuvant delivery system owned by Mercia Pharma, induced highly significant increases in specific anti-HBV (hepatitis B virus) antibodies. These findings were presented by Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology at CEL-SCI at the 10th Annual Conference of the National Foundation for Infectious Diseases in Baltimore, Maryland.

This new finding with CEL-1000 may have broad application for the enhancement of immune responses by individuals who have a poor immune response to vaccinations. It also has application for antigen sparing (reducing the amount/dose of antigen) required for protective immunity, and application to biodefense and pandemic settings for anti-infectious vaccines.

Dr. Zimmerman said, "A good number of people, a great majority of them middle aged and older men, vaccinated against Hepatitis B fail to generate high enough levels of antibodies to be considered protected. These individuals need and deserve a better level of protection."

CEL-1000 has previously been shown to be protective in animal challenge studies against viruses and unrelated diseases, specifically herpes simplex virus, viral encephalitis and malaria. CEL-1000 appears to activate innate (very early stage) and Th1 type (cellular) immune responses to induce a broad- spectrum protection against infection in animal models. The innate immune system is generally accepted to be the first line of defense against infectious agents.

CEL-1000, derived from the beta chain of human MHC-II, is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host's protective imm
'"/>




Page: 1 2

Related medicine technology :

1. RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
2. Gabapentin Shown Effective for Fibromyalgia Pain
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
5. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
6. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
7. RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer
8. Accelreon Pharmas ACE-031Shown to Increase Muscle Mass in Preclinical Studies
9. Cethromycin Shown Effective Against Anthrax in Study
10. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
11. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
Post Your Comments:
(Date:5/23/2013)... -- BioElectronics Corporation (OTC Pink: BIEL), the maker of very ... panel meeting for non-thermal shortwave diathermy: The ... Meeting was held on May 21, 2013 in ... the meeting was very narrow, in that the FDA ... application of non-thermal shortwave diathermy for the treatment of ...
(Date:5/23/2013)... 23, 2013  Intercept Pharmaceuticals, Inc. (Nasdaq: ... on the development and commercialization of novel bile acid ... biliary cirrhosis, today announced that Mark Pruzanski ... present at the Deutsche Bank Securities 38th Annual Health ... Wednesday, May 29, 2013 at 4:10 p.m. ET. ...
(Date:5/23/2013)...  Inhibikase Therapeutics, Inc., an emerging leader in ... present new results on its antiviral program to ... the PML Consortium (composed of Pfizer, Bristol-Meyers Squibb, ... the causative agent of Progressive Multifocal Leukoencephalopathy (PML). ... extended release formulation, can clear JC polyomavirus (JCV) ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2
... Announces Clinical Trial Plans for 4Q07/1Q08, DALLAS, ... ACCP) provided today an update on the clinical,development ... prodrug, and,announced plans for additional human clinical trials ... ongoing clinical trial in recurrent ovarian,cancer patients, designed ...
... ... Study -, ... has initiated a multi-dose, Phase 2a clinical trial with,its monoclonal antibody ... dose-escalation study is,designed to evaluate the safety and tolerability of multiple ...
Cached Medicine Technology:Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 2Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 3Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac 4MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma 2
(Date:5/23/2013)... May 24, 2013 On March 14, 2012, ... women will hear in her lifetime: she had breast cancer. ... Journey After a Breast Cancer Diagnosis ” (published by AuthorHouse), ... , Rideout drew from her daily journals to give readers ... surgery, chemotherapy and radiation treatments to deal with stage two ...
(Date:5/23/2013)... If you are one of the estimated ... the food spread this Memorial Day weekend could put ... dogs and ice cream have become cornerstones of the ... sufferers often feel the painful effects of consuming these ... Lourdes Medical Associates. , IBS occurs when the large ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Amirsys, ... comprehensive radiology learning environment for all resident levels ... and assessments, transforms the learning experience from case-based ... , “Until RADPrimer 3.0, RADPrimer heavily ... none,” comments Dr. B.J. Manaster, Professor of Radiology ...
(Date:5/23/2013)... 2013)Don,t doubt it when a woman harried by hot ... A new study published online in Menopause , ... helps confirm with objective tests that what these women ... past, some studies showed that hot flashes were related ... that, even though there was a relationship between hot ...
(Date:5/23/2013)... being dragged to its destruction inside a cell, ... signals that thwart the development of tumor-suppressing microRNAs ... early online publication at Nature . , ... tumors, the epidermal growth factor receptor (EGFR) gums ... led by scientists at The University of Texas ...
Breaking Medicine News(10 mins):Health News:Kimberley Rideout Shares Her Triumphant Cancer Survival Story 2Health News:Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend 2Health News:Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend 3Health News:RADPrimer 3.0 Introduces Comprehensive Radiology Training Curriculum 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3
... WASHINGTON, Dec. 18 - In response to the,press ... E. Schumer (D-NY) of a bill -- S ... (DARA 2007)," -- which proposes to amend,the Controlled ... to minors and,create penalties to those who would ...
... America, the,fastest-growing Hispanic television network in the United States, ... this week,s broadcast of "Issues:,Caras y Voces" (Issues: Faces ... Dr. Huerta is the first Latino to assume the ... studied medicine at the University of San,Marcos and Johns ...
... Dec. 18 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals,Corporation (NASDAQ: ... British,Columbia Supreme Court has issued a final order ... (SWX: GALN), through a wholly-owned,Canadian subsidiary, will acquire ... US$26.00 per share in cash., The transaction, ...
... 18 Alsius Corporation,(Nasdaq: ALUS ), which ... announced today that the company has,launched offers to ... opportunity, for a limited time, to exercise the ... terms of the warrants to allow holders to,receive ...
... Royalty Pharma and Northwestern,University announced today that Northwestern ... in Lyrica(R) to Royalty Pharma for $700 million,in ... A portion of the payment to Northwestern will ... chemical compound that serves as the basis for,Lyrica(R)., ...
... SAN DIEGO, Dec. 18 Pacira Pharmaceuticals, ... today announced that,David M. Stack has been ... of the Board of Directors., (Logo: ... currently the CEO and founding partner of ...
Cached Medicine News:Health News:Council for Responsible Nutrition Calls Proposed DHEA Legislation 'A Solution in Search of a Problem' 2Health News:American Cancer Society President Elmer Huerta Shares Inspirational Message on Azteca America's 'Issues: Caras Y Voces' 2Health News:Aspreva receives final court approval for acquisition by Galenica 2Health News:Aspreva receives final court approval for acquisition by Galenica 3Health News:Aspreva receives final court approval for acquisition by Galenica 4Health News:Alsius Corporation Announces Program for Early Exercise of Warrants 2Health News:Alsius Corporation Announces Program for Early Exercise of Warrants 3Health News:Alsius Corporation Announces Program for Early Exercise of Warrants 4Health News:Royalty Pharma Acquires a Portion of Northwestern University's Royalty Interest in Lyrica(R) for $700 Million 2Health News:Royalty Pharma Acquires a Portion of Northwestern University's Royalty Interest in Lyrica(R) for $700 Million 3Health News:Pacira Pharmaceuticals Names David M. Stack CEO and President 2Health News:Pacira Pharmaceuticals Names David M. Stack CEO and President 3
... The Accustrip Strep A(ll) Test ... immunoassay for the rapid, qualitative ... antigen from throat swabs. The ... as an aid in the ...
HemataSTAT II has a manual reader. It uses both 0.5 and 1.1 ID capillary tubes., , Spins in just 60 seconds , Built-in reader with LCD display , Accuracy comparable to NCCLS reference method , Lid lo...
The INRatio meter is a diagnostic Point Of Care system that provides Prothrombin Time (PT) and International Normalized Ratio (INR) results using one drop of fresh capillary whole blood from a finger...
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
Medicine Products: